KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)–naive patients with metastatic castration-resistant prostate cancer (mCRPC)
Todenhöfer, T., Piulats, J.M., Ferrario, C., Linch, M.D., Stoeckle, M., Laguerre, B., Arranz, J.A., Fong, P.C.C., Berry, W.R., Emmenegger, U., Mourey, L., Mar, N., Appleman, L.J., Joshua, A.M., Conter, H.J., Li, X.T., Schloss, C., Poehlein, C.H., De Bono, J.S., Yu, E.Y.
Published in European urology (01.02.2022)
Published in European urology (01.02.2022)
Get full text
Journal Article
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide
Rathkopf, D.E., Smith, M.R., Ryan, C.J., Berry, W.R., Shore, N.D., Liu, G., Higano, C.S., Alumkal, J.J., Hauke, R., Tutrone, R.F., Saleh, M., Chow Maneval, E., Thomas, S., Ricci, D.S., Yu, M.K., de Boer, C.J., Trinh, A., Kheoh, T., Bandekar, R., Scher, H.I., Antonarakis, E.S.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
217O Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study
Joshua, A.M., Gurney, H., Retz, M., Tafreshi, A., Fong, P.C.C., Shore, N.D., Romano, E., Augustin, M., Piulats, J.M., Berry, W.R., Kolinsky, M.P., Sridhar, S.S., Conter, H.J., Todenhöfer, T., Appleman, L.J., Wu, H., Schloss, C., Poehlein, C.H., de Bono, J.S., Yu, E.Y.
Published in Annals of oncology (01.11.2020)
Published in Annals of oncology (01.11.2020)
Get full text
Journal Article
620P Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update
Romano, E., Sridhar, S.S., Kolinsky, M.P., Gravis, G., Mourey, L., Piulats, J.M., Berry, W.R., Gurney, H., Retz, M., Appleman, L.J., Boegemann, M., de Bono, J.S., Joshua, A.M., Emmenegger, U., Conter, H.J., Laguerre, B., Wu, H., Qiu, P., Schloss, C., Yu, E.Y.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update
Mourey, L., Conter, H.J., Shore, N., Berry, W.R., Fong, P.C., Piulats, J.M., Appleman, L.J., Todenhöfer, T., Gravis, G., Laguerre, B., Gurney, H., Retz, M., Romano, E., de Bono, J.S., Kam, A.E., Emmenegger, U., Wu, H., Qiu, P., Schloss, C., Yu, E.Y.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer
Koontz, B.F., Hoffman, K.E., Oyekunle, T., George, D.J., Zhang, T., Berry, W.R., Lee, W.R., Harrison, M.R., Corn, P.G., Halabi, S., Armstrong, A.
Published in International journal of radiation oncology, biology, physics (01.11.2021)
Published in International journal of radiation oncology, biology, physics (01.11.2021)
Get full text
Journal Article
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
Sonpavde, G., Matveev, V., Burke, J.M., Caton, J.R., Fleming, M.T., Hutson, T.E., Galsky, M.D., Berry, W.R., Karlov, P., Holmlund, J.T., Wood, B.A., Brookes, M., Leopold, L.
Published in Annals of oncology (01.07.2012)
Published in Annals of oncology (01.07.2012)
Get full text
Journal Article
621P Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update
Arranz Arija, J.A., Yu, E.Y., Piulats, J.M., Gravis, G., Laguerre, B., Oudard, S., Fong, P.C., Kolinsky, M.P., Augustin, M., Todenhöfer, T., Kam, A.E., Gurney, H., Tafreshi, A., Retz, M., Berry, W.R., Mar, N., Wu, H., Qiu, P., Schloss, C., de Bono, J.S.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer
Koontz, B.F., Hoffman, K.E., Healy, P., George, D.J., Harrison, M.R., Zhang, T., Lee, W.R., Berry, W.R., Pugh, T.J., Bratt, L., Hobbs, B., Halabi, S., Corn, P.G., Armstrong, A., Shobe, K., Tojong, B., Thornburg, B., Brummer, K., Allen, D.
Published in International journal of radiation oncology, biology, physics (01.11.2018)
Published in International journal of radiation oncology, biology, physics (01.11.2018)
Get full text
Journal Article
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
Sonpavde, G., Periman, P.O., Bernold, D., Weckstein, D., Fleming, M.T., Galsky, M.D., Berry, W.R., Zhan, F., Boehm, K.A., Asmar, L., Hutson, T.E.
Published in Annals of oncology (01.02.2010)
Published in Annals of oncology (01.02.2010)
Get full text
Journal Article